Your browser doesn't support javascript.
loading
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.
Delord, Jean-Pierre; Robert, Caroline; Nyakas, Marta; McArthur, Grant A; Kudchakar, Ragini; Mahipal, Amit; Yamada, Yasuhide; Sullivan, Ryan; Arance, Ana; Kefford, Richard F; Carlino, Matteo S; Hidalgo, Manuel; Gomez-Roca, Carlos; Michel, Daniela; Seroutou, Abdelkader; Aslanis, Vassilios; Caponigro, Giordano; Stuart, Darrin D; Moutouh-de Parseval, Laure; Demuth, Tim; Dummer, Reinhard.
Afiliação
  • Delord JP; Institut Universitaire du Cancer, Toulouse, France. delord.jean-pierre@iuct-oncopole.fr.
  • Robert C; Gustave Roussy and Paris-Sud University, Villejuif, France.
  • Nyakas M; Oslo University Hospital, Norway.
  • McArthur GA; Peter MacCallum Cancer Centre and the University of Melbourne, Australia.
  • Kudchakar R; Winship Cancer Institute of Emory University, Atlanta, Georgia.
  • Mahipal A; Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Yamada Y; National Cancer Center Hospital, Tokyo, Japan.
  • Sullivan R; Massachusetts General Hospital, Boston, Massachusetts.
  • Arance A; Department of Medical Oncology and Translational Genomics and Targeted Therapeutics in Solid Tumors, Hospital Clínic, Barcelona, Spain.
  • Kefford RF; Crown Princess Mary Cancer Centre Westmead Hospital, Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia.
  • Carlino MS; Macquarie University, Sydney, New South Wales, Australia.
  • Hidalgo M; Crown Princess Mary Cancer Centre Westmead Hospital, Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia.
  • Gomez-Roca C; Spanish National Cancer Research Centre (CNIO) and Centro Integral Oncologico Clara Campal, Madrid, Spain.
  • Michel D; Institut Universitaire du Cancer, Toulouse, France.
  • Seroutou A; Novartis Pharma AG, Basel, Switzerland.
  • Aslanis V; Novartis Pharma AG, Basel, Switzerland.
  • Caponigro G; Novartis Pharma AG, Basel, Switzerland.
  • Stuart DD; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Moutouh-de Parseval L; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
  • Demuth T; Novartis Pharma AG, Basel, Switzerland.
  • Dummer R; Novartis Pharma AG, Basel, Switzerland.
Clin Cancer Res ; 23(18): 5339-5348, 2017 Sep 15.
Article em En | MEDLINE | ID: mdl-28611198
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Carbamatos / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Melanoma / Mutação / Antineoplásicos Limite: Animals / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Carbamatos / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Melanoma / Mutação / Antineoplásicos Limite: Animals / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França